Teachers Retirement System of The State of Kentucky acquired a new position in Assembly Biosciences Inc (NASDAQ:ASMB) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,550 shares of the biopharmaceutical company’s stock, valued at approximately $540,000. Teachers Retirement System of The State of Kentucky owned 0.06% of Assembly Biosciences at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Bank of Montreal Can bought a new stake in shares of Assembly Biosciences during the second quarter valued at approximately $145,000. TD Asset Management Inc. increased its position in shares of Assembly Biosciences by 20.5% during the second quarter. TD Asset Management Inc. now owns 9,400 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 1,600 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Assembly Biosciences by 14.9% during the second quarter. Commonwealth Equity Services LLC now owns 10,497 shares of the biopharmaceutical company’s stock valued at $412,000 after acquiring an additional 1,365 shares in the last quarter. Alps Advisors Inc. bought a new stake in shares of Assembly Biosciences during the second quarter valued at approximately $1,169,000. Finally, State of Wisconsin Investment Board grew its position in Assembly Biosciences by 57.3% in the 2nd quarter. State of Wisconsin Investment Board now owns 17,300 shares of the biopharmaceutical company’s stock worth $678,000 after purchasing an additional 6,300 shares during the period. Hedge funds and other institutional investors own 84.94% of the company’s stock.
A number of equities research analysts have commented on ASMB shares. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 3rd. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Monday, October 8th. Leerink Swann started coverage on shares of Assembly Biosciences in a research report on Monday, November 19th. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Assembly Biosciences has a consensus rating of “Buy” and an average target price of $52.00.
Shares of Assembly Biosciences stock opened at $25.01 on Friday. The firm has a market cap of $628.69 million, a PE ratio of -10.38 and a beta of 1.45. Assembly Biosciences Inc has a 1-year low of $20.61 and a 1-year high of $67.36.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.01) by $0.14. The business had revenue of $4.29 million for the quarter, compared to analysts’ expectations of $3.21 million. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%. As a group, equities research analysts forecast that Assembly Biosciences Inc will post -4.02 earnings per share for the current fiscal year.
WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/12/07/teachers-retirement-system-of-the-state-of-kentucky-acquires-shares-of-14550-assembly-biosciences-inc-asmb.html.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Featured Story: What is Cost of Capital?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.